Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Mitoxantrone Liposome in R/R AML
NCT05522192Phase 2Recruiting
- Start
- Jul 2022
- Primary completion
- Nov 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone-liposome in acute myeloid leukemia (AML). Started Jul 2022; status: recruiting.
02
Drugs
mitoxantrone-liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05522192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522192.